Health Canada approved the first generic version of the diabetes medication Ozempic, known as semaglutide, on April 28, 2026 [1], [2].
This decision is significant because it introduces a lower-cost alternative for patients in a market previously dominated by a single brand. By authorizing the generic, Canada becomes the first G7 nation to allow a generic version of semaglutide [3], [4].
The federal regulator's move aims to increase the affordability of the drug for Canadian patients. A spokesperson for Health Canada said, "Today, Health Canada has approved a generic semaglutide injection" [3].
Ozempic has seen a surge in demand globally, often leading to supply shortages and high costs for those without comprehensive insurance. Valérie-Micaela Bain said that buying Ozempic will soon cost Canadian patients less [5].
While the approval marks a regulatory milestone, the generic version is not yet covered by insurance. The availability of the drug will depend on pharmacy distribution, and provincial health coverage updates. Health Canada said, "Canada is the first G7 country to authorize generic semaglutide" [4].
The approval follows a rigorous review process to ensure the generic version maintains the same efficacy and safety profiles as the original Novo Nordisk product. This regulatory step allows other manufacturers to enter the market, potentially increasing the total supply of the medication within the country [3], [6].
“Canada is the first G7 country to authorize generic semaglutide.”
Canada's decision to lead the G7 in approving generic semaglutide signals a shift toward prioritizing drug affordability and supply chain resilience. By breaking the monopoly on this high-demand medication, the Canadian government is attempting to lower the financial barrier for diabetes patients and reduce the impact of global shortages. This move may pressure other G7 regulators to accelerate their own generic approval processes for similar GLP-1 receptor agonists.
